

MELOXIWAY 5mg/mL INJECTION

ACTIVE CONSTITUENT:

MELOXICAM 5mg/mL

NET CONTENTS:

10m and 20mL

CLAIMS:

Dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.

Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs.

Cats - reduction of pain after surgery. Management of febrile conditions in combination with appropriate antibiotics.



GENERAL DIRECTIONS:

Composition clear yellow solution containing 5 mg meloxicam per ml (and 150 mg of ethanol as preservative).

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.

Hypovolaemia or hypotension should be corrected prior to use of the product.

Overdosage: In case of overdosing a symptomatic treatment should be initiated.

DOSAGE AND ADMINISTRATION

Discard unused product 28 days after first broaching vial.

Dogs:

Musculoskeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 mL /10 kg bodyweight). Meloxiway 5 mg/ml Injection should be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.

Reduction of post-operative pain:

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 mL /10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (ie. 0.06 mL kg bodyweight) directly prior to induction of anaesthesia

Management of febrile conditions: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (ie. 0.06 ml/kg bodyweight).



DIRECTIONS FOR USE

PRECAUTIONS:

Cats: MELOXIWAY 5mg/mL Injection should be used as a single dose of 0.3 mg meloxicam/kg. Safety trials have demonstrated that meloxicam when administered subcutaneously at 0.3 mg/kg at 24 hour intervals for 3 consecutive days in cats, resulted in no side effects in trial animals.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects.

MELOXIWAY 5mg/mL Injection must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pretreatment with other anti-inflammatory drugs prior to the use of MELOXIWAY 5mg/mL Injection may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with MELOXIWAY 5mg/mL Injection.

The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs previously used.

The use of this product in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

SIDE EFFECTS:

Parenteral administration of MELOXIWAY 5mg/mL Injection for dogs and cats is well tolerated without local adverse reactions.

Typical adverse reactions of NSAIDs may occur (particularly within the first 5-14 days of treatment). These may include loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and apathy.

In very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration and elevated liver enzymes have been reported.

In most cases, gastrointestinal side effects are transient and disappear following termination of treatment, however in rare cases this may be serious. Symptomatic treatment may be necessary. Owners should be advised to discontinue therapy and contact their veterinarian if signs of intolerance are observed.

CONTRAINDICATIONS:

This product is contraindicated for use in pregnant or lactating animals as no data has been established.

This product is contraindicated for use in animals less than 6 weeks of age.

This product is contraindicated for use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product.

First Aid Instructions:

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Disposal:

Dispose of empty container by wrapping with paper and putting in garbage.

STORAGE

Store below 25°C (Air Conditioning).

APVMA Approval No.: 87816/135602

